Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancer
Phase 1
- Conditions
- Metastatic colorectal cancer
- Registration Number
- JPRN-jRCT2080220022
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
PS=0-2, Age < 75 yrs, with target leasion according to RECEST
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Initial safety, PK parameter of bevacizumab
- Secondary Outcome Measures
Name Time Method